Drug Trial Radar · NCT04304144
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
Last checked: Nov 19, 2026Latest source record: Mar 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Mar 18, 2020
Primary completion
Nov 14, 2023
Study completion Nov 14, 2023
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AL amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine the recommended dose of CAEL-101 to facilitate progression of further clinical trials and evaluate safety and tolerability of CAEL-101 in combination with the standard of care (SoC) cyclophosphamide-bortezomib-dexamethasone (CyBorD) chemotherapy and daratumumab .
Conditions
- AL Amyloidosis
Interventions
CAEL-101Drug
The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)Drug
According to institutional standard of care.
DaratumumabDrug
Treatment for AL amyloidosis
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) and Adverse Events (AEs), and AEs Leading to Treatment DiscontinuationTime frame: First dose of study drug until 140 days after last dose of study drug (Maximum exposure: 38.90 months for Part A and 32.50 months for Part B)
- Number of Participants With Dose-limiting Toxicity (DLT) During the First 4 Weeks of TherapyTime frame: 4 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Stanford, California
Research Site
Detroit, Michigan
Research Site
Cleveland, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.